Percutaneous tibial nerve stimulation: A clinicallyand cost effective addition to the overactive bladder algorithm of care

Current Urology Reports

Volumn 13, Issue 5, 2012, Pages 327-334

  Staskin, David R ^a,f   Peters, Kenneth M ^b   MacDiarmid, Scott ^c   Shore, Neal ^d   De Groat, William C ^e  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WILLIAM BEAUMONT HOSPITAL   (United States)

^c Alliance Urology Specialists   (United States)

^d Carolina Urologic Research Center   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f ST ELIZABETH'S MEDICAL CENTER   (United States)

Author keywords

Cost benefit; Electric stimulation therapy; Electrodes; Overactive; Overactive detrusor activity; Stimulation; Urinary bladder

Indexed keywords

MUSCARINIC RECEPTOR BLOCKING AGENT; PLACEBO; TOLTERODINE;

ADVERSE OUTCOME; CLINICAL EFFECTIVENESS; CONSERVATIVE TREATMENT; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; INJECTION SITE BLEEDING; INJECTION SITE CONTUSION; INJECTION SITE PAIN; MICTURITION DISORDER; MICTURITION REFLEX; NERVE STIMULATION; NEUROMODULATION; OUTCOME ASSESSMENT; OUTPATIENT CARE; OVERACTIVE BLADDER; PATIENT COMPLIANCE; PATIENT SAFETY; PERCUTANEOUS TIBIAL NERVE STIMULATION; QUALITY OF LIFE; REVIEW; SACRAL NERVE STIMULATION; SKIN TINGLING; TIBIAL NERVE; URINARY TRACT INFECTION; XEROSTOMIA;

ADULT; ALGORITHMS; COST-BENEFIT ANALYSIS; ELECTRIC STIMULATION THERAPY; ELECTRODES, IMPLANTED; FEMALE; HUMANS; LUMBOSACRAL PLEXUS; MALE; MUSCARINIC ANTAGONISTS; QUALITY OF LIFE; TIBIAL NERVE; TREATMENT OUTCOME; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84869234126     PISSN: 15272737     EISSN: 15346285     Source Type: Journal    
DOI: 10.1007/s11934-012-0274-9     Document Type: Review

References (40)

1. Gormley EA, Lightner DJ, Burgio KL, Chai TC, Clemens JQ, Culkin DJ, et al. Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU Guideline. 2012. The AUA/SUFU Guidelines for treatment and diagnosis of OAB present a thorough and definitive approach to the patient with OAB, including behavioral interventions, antimuscarinic drugs, and neuromodulation with PTNS and SNS.
2. Finazzi-Agro E, Petta F, Sciobica F, Pasqualetti P, Musco S, Bove P. Percutaneous tibial nerve stimulation effects on detrusor overactivity incontinence are not due to a placebo effect: a randomized, double-blind, placebo controlled trial. J Urol. 2010; 184(5): 2001-6. doi: 10.1016/j.juro.2010.06.113.
3. Govier FE, Litwiller S, Nitti V, Kreder Jr KJ, Rosenblatt P. Percutaneous afferent neuromodulation for the refractory overactive bladder: results of a multicenter study. J Urol. 2001; 165 (4): 1193-8. (Pubitemid 32210239)
4. MacDiarmid SA, Peters KM, Shobeiri SA,Wooldridge LS, Rovner ES, Leong FC, et al. Long-term durability of percutaneous tibial nerve stimulation for the treatment of overactive bladder. J Urol. 2010; 183 (1): 234-40. doi: 10.1016/j.juro.2009.08.160. This is the 12 month follow- on study to the OrBIT study comparing UPC and tolterodine, originally published by study Peters KM,MacDiarmid SA,Wooldridge L, et al, showing sustained symptom improvement for PTNS responders.
5. Peters KM, Carrico DJ, Perez-Marrero RA, Khan AU, Wooldridge LS, Davis GL, et al. Randomized trial of percutaneous tibial nerve stimulation versus Sham efficacy in the treatment of overactive bladder syndrome: results from the SUmiT trial. J Urol. 2010; 183(4): 1438-43. doi: 10.1016/j.juro.2009.12.036. This paper presents the data from a randomized, placebo-controlled study of PTNS versus a sham treatment. This paper presents Level 1 evidence of effectiveness of PTNS.
6. Peters KM, Macdiarmid SA, Wooldridge LS, Leong FC, Shobeiri SA, Rovner ES, et al. Randomized trial of percutaneous tibial nerve stimulation versus extended-release tolterodine: results from the overactive bladder innovative therapy trial. J Urol. 2009; 182(3): 1055-61. doi: 10.1016/j.juro.2009.05.045. This is one of the randomized, controlled studies of PTNS, and demonstrates comparable response rates of patients treated with PTNS versus tolterodine.
7. Vandoninck V, van Balken MR, Finazzi Agro E, Petta F, Micali F, Heesakkers JP, et al. Percutaneous tibial nerve stimulation in the treatment of overactive bladder: urodynamic data. Neurourol Urodyn. 2003; 22(3): 227-32. doi: 10.1002/nau.10111. This paper provides urodynamic data on patients treated with PTNS, and supplements the subjective data (frequency, urgency, bother) presented in the randomized, controlled studies of PTNS. (Pubitemid 36532301)
8. National Institute for Health and Clinical Excellence. Percutaneous tibial nerve stimulation for overactive bladder symptoms. 2010. http: //www.nice.org.uk/nicemedia/live/12412/51304/51304.pdf. Accessed 27 Oct 2010.
9. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, et al. Prevalence and burden of overactive bladder in the United States. World J Urol. 2003; 20(6): 327-36. doi: 10.1007/ s00345-002-0301-4. (Pubitemid 44175300)
10. Abrams P. Describing bladder storage function: overactive bladder syndrome and detrusor overactivity. Urology. 2003; 62(5 Suppl 2): 28-37. discussion 40-2. (Pubitemid 37510015)
11. Nygaard I. Clinical practice. Idiopathic urgency urinary incontinence. N Engl J Med. 2010; 363(12): 1156-62. doi: 10.1056/ NEJMcp1003849.
12. GanzML, Smalarz AM,Krupski TL,Anger JT,Hu JC,Wittrup-Jensen KU, et al. Economic costs of overactive bladder in the United States. Urology. 2010; 75(3): 526-32. doi: 10.1016/j.urology.2009.06.096. 32 e1-18.
13. Brown JS, McGhan WF, Chokroverty S. Comorbidities associated with overactive bladder. Am J Manage Care. 2000; 6: S574-9. (Pubitemid 30649378)
14. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population based prevalence study. BJU Int. 2001; 87: 760-6. (Pubitemid 34204313)
15. McPherson A. The effects of somatic stimuli on the bladder in the cat. J Physiol. 1966; 185(1): 185-96.
16. McPherson A. Vesico-somatic reflexes in the chronic spinal cat. J Physiol. 1966; 185(1): 197-204.
17. Sato A, Sato Y, Schmidt RF, Torigata Y. Somato-vesical reflexes in chronic spinal cats. J Auton Nerv Syst. 1983; 7: 351-62. (Pubitemid 13098318)
18. McGuire E, Morrissey S, Zhang S, Horwinski E. Control of reflex detrusor activity in normal and spinal injured non-human primates. J Urol. 1983; 129(1): 197-9. (Pubitemid 13148093)
19. McGuire EJ, Zhang SC, Horwinski ER, Lytton B. Treatment of motor and sensory detrusor instability by electrical stimulation. J Urol. 1983; 129(1): 78-9. (Pubitemid 13148056)
20. Tai C, Shen B, Chen M, Wang J, Roppolo JR, de Groat WC. Prolonged poststimulation inhibition of bladder activity induced by tibial nerve stimulation in cats. Am J Physiol Ren Physiol. 2011; 300(2): F385-92. doi: 10.1152/ajprenal.00526.2010.
21. Herbison GP, Arnold EP. Sacral neuromodulation with implanted devices for urinary storage and voiding dysfunction in adults. Cochrane Database Syst Rev. 2009; Suppl 2: CD004202. doi: 10.1002/14651858.CD004202.pub2.
22. Klingler HC, Pycha A, Schmidbauer J, Marberger M. Use of peripheral neuromodulation of the S3 region for treatment of detrusor overactivity: a urodynamic-based study. Urology. 2000; 56(5): 766-71.
23. Vandoninck V, van Balken MR, Finazzi Agro E, Heesakkers JP, Debruyne FM, Kiemeney LA, et al. Posterior tibial nerve stimulation in the treatment of voiding dysfunction: urodynamic data. Neurourol Urodyn. 2004; 23(3): 246-51. doi: 10.1002/nau.10158. (Pubitemid 39549984)
24. van Leeuwen JH, Castro R, Busse M, Bemelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol. 2006; 50(3): 440-52. doi: 10.1016/ j.eururo.2006.05.014. discussion 53.
25. Payne CK, Kelleher C. Redefining response in overactive bladder syndrome. BJU Int. 2007; 99: 101-6. (Pubitemid 44915628)
26. Peters KM, Carrico DJ, Macdiarmid SA, Wooldridge LS, Khan AU, McCoy CE et al. Sustained therapeutic effects of percutaneous tibial nerve stimulation: 24-month results of the STEP study. LID - doi: 10.1002/nau.22266. (1520-6777 (Electronic)). This is the 24 month follow-on study to the SUmiTstudy, originally published by Peters KM, Carrico DJ, Perez-Marrero RA, et al, showing 24 month sustained symptom improvement for PTNS responders.
27. Chapple C, Khullar V, Gabriel Z, Dooley JA. The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta-analysis. Eur Urol. 2005; 48(1): 5-26. doi: 10.1016/j. eururo. 2005.02.024. This is a systematic review of the antimuscarinic drugs that have been tested for efficacy in OAB, and provides headto- head comparison in outcome measures as well as side effects. This is the latest in a series of systematic reviews, and builds upon reviews done in 2003 and 2005 by the same authors. (Pubitemid 40835585)
28. Burton C, Sajja A, Latthe PM. Effectiveness of percutaneous posterior tibial nerve stimulation for overactive bladder: A systematic review and meta-analysis. LID - doi: 10.1002/nau.22251. (1520-6777 (Electronic)).
29. Shamliyan T,Wyman J, Kane RL. Nonsurgical treatments for urinary incontinence in adult women: Diagnosis and comparative effectiveness. Rockville, MD: Agency for Healthcare Research and Quality2012. Report No.: AHRQ Publication No. 11(12)-EHC074-EF.
30. Cameron AP, Anger JT, Madison R, Saigal CS, Clemens JQ. National trends in the usage and success of sacral nerve test stimulation. J Urol. 2011; 185(3): 970-5. doi: 10.1016/j.juro.2010.10.060.
31. Schmidt RA, Jonas U, Oleson KA, Janknegt RA, Hassouna MM, Siegel SW, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. J Urol. 1999; 162: 352-7. (Pubitemid 29434339)
32. Kessler TM, Bachmann LM, Minder C, Lohrer D, Umbehr M, Schunemann HJ, et al. Adverse event assessment of antimuscarinics for treating overactive bladder: a network metaanalytic approach. PLoS One. 2011; 6(2): e16718. doi: 10.1371/ journal.pone.0016718.
33. Yalcin I, Bump RC. Validation of two global impression questionaires for incontinence. Am J Obstet Gynecol. 2003; 189: 98-100.
34. Peters KM, Killinger KA, Ibrahim AM, Villaba PS. The relationship between subjective and objective assessments of sacral neuromodulation effectiveness in patients with urgency-frequency. Neurourol Urodyn. 2008; 27: 775-8. This paper reviews the value of the subjective measurements (urgency, frequency, bother) that underpin evaluation of the effectiveness of treatments for OAB. Since OAB is largely a disease of symptoms, subjective measures are critical to the evaluation of effectiveness; fortunately, subjective measurements typically follow objective measurements.
35. Khullar V, Chapple C, Gabriel Z, Dooley JA. The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology. 2006; 68 (2): 38-48. doi: 10.1016/j.urology.2006.05.043. (Pubitemid 44189489)
36. Gopal M, Haynes K, Bellamy SL, Arya LA. Discontinuation rates of anticholinergic medications used for the treatment of lower urinary tract symptoms. Obstet Gynecol. 2008; 112(6): 1311-8. doi: 10.1097/AOG. 0b013e31818e8aa4. This paper shows the discouraging rate of discontinuance of anticholinergic medications used for OAB. Although pharmacologic studies uniformly demonstrate efficacy, in the real world patients either do not receive sufficient benefit, or the side effects are intolerable for the patients to continue. Most patients get only a few months benefit from drug therapy before they discontinue taking the medications.
37. Hartmann KE, McPheeters ML, Biller DH, Ward RM, McKoy JN, Jerome RN, et al. Treatment of overactive bladder in women. Evid Rep Technol Assess (Full Rep). 2009; Suppl 187: 1-120, v.
38. http: //www.healthcare.utah.edu/pharmacy/bulletins/NDB-188.pdf. Accessed 14 Jul 2012.
39. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost analysis of interventions for antimuscarinic refractory patients with overactive bladder. Urology. 2010; 76 (4): 835-40. doi: 10.1016/j.urology.2010. 01.080.
40. Woodbridge LS. Percutaneous tibial nerve stimulation for the treatment of urinary frequency, urgency, and urge incontinence: results from a community based clinic. Urol Nurs. 2009; 29: 177-85.